Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy.
Kaňovský P, Heinen F, Schroeder AS, Chambers HG, Dabrowski E, Geister TL, Hanschmann A, Martinez-Torres FJ, Pulte I, Banach M, Gaebler-Spira D. Kaňovský P, et al. J Pediatr Rehabil Med. 2022;15(1):113-127. doi: 10.3233/PRM-210041. J Pediatr Rehabil Med. 2022. PMID: 34957963 Free PMC article. Clinical Trial.
IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study.
Heinen F, Kanovský P, Schroeder AS, Chambers HG, Dabrowski E, Geister TL, Hanschmann A, Martinez-Torres FJ, Pulte I, Banach M, Gaebler-Spira D. Heinen F, et al. Among authors: kanovsky p. J Pediatr Rehabil Med. 2021;14(2):183-197. doi: 10.3233/PRM-210040. J Pediatr Rehabil Med. 2021. PMID: 34092664 Free PMC article. Clinical Trial.
Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, Jech R, Roth J, Brenneis C, Müller J, Schnider P, Auff E, Richardson A, Poewe W. Wissel J, et al. Among authors: kanovsky p. J Neurol. 2001 Dec;248(12):1073-8. doi: 10.1007/s004150170028. J Neurol. 2001. PMID: 12013585 Clinical Trial.
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA. Dressler D, et al. Among authors: kanovsky p. J Neurol. 2017 Jan;264(1):112-120. doi: 10.1007/s00415-016-8304-z. Epub 2016 Oct 27. J Neurol. 2017. PMID: 27787630 Review.
Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy.
Dressler D, Bhidayasiri R, Bohlega S, Chana P, Chien HF, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kanovsky P, Koçer S, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA. Dressler D, et al. Among authors: kanovsky p. J Neurol. 2018 Apr;265(4):856-862. doi: 10.1007/s00415-018-8759-1. Epub 2018 Feb 8. J Neurol. 2018. PMID: 29423615
222 results